293 related articles for article (PubMed ID: 19751918)
41. Rivastigmine for Alzheimer's disease.
Birks J; Iakovidou V; Tsolaki M
Cochrane Database Syst Rev; 2000; (2):CD001191. PubMed ID: 10796621
[TBL] [Abstract][Full Text] [Related]
42. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Pomara N; Ott BR; Peskind E; Resnick EM
Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
[TBL] [Abstract][Full Text] [Related]
43. Donepezil for dementia due to Alzheimer's disease.
Birks J; Harvey RJ
Cochrane Database Syst Rev; 2006 Jan; (1):CD001190. PubMed ID: 16437430
[TBL] [Abstract][Full Text] [Related]
44. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
45. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
Bernick C; Cummings J; Raman R; Sun X; Aisen P
Arch Neurol; 2012 Jul; 69(7):901-5. PubMed ID: 22431834
[TBL] [Abstract][Full Text] [Related]
46. Rivastigmine for Alzheimer's disease.
Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
[TBL] [Abstract][Full Text] [Related]
47. Metrifonate for Alzheimer's disease.
López-Arrieta JM; Schneider L
Cochrane Database Syst Rev; 2006 Apr; (2):CD003155. PubMed ID: 16625573
[TBL] [Abstract][Full Text] [Related]
48. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
[TBL] [Abstract][Full Text] [Related]
49. Donepezil for dementia due to Alzheimer's disease.
Birks JS; Harvey R
Cochrane Database Syst Rev; 2003; (3):CD001190. PubMed ID: 12917900
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
51. Memantine for dementia.
Areosa SA; Sherriff F; McShane R
Cochrane Database Syst Rev; 2005 Jul; (3):CD003154. PubMed ID: 16034889
[TBL] [Abstract][Full Text] [Related]
52. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.
Pasqualetti P; Bonomini C; Dal Forno G; Paulon L; Sinforiani E; Marra C; Zanetti O; Rossini PM
Aging Clin Exp Res; 2009 Apr; 21(2):102-10. PubMed ID: 19448381
[TBL] [Abstract][Full Text] [Related]
53. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
[TBL] [Abstract][Full Text] [Related]
55. Metrifonate treatment of AD: influence of APOE genotype.
Farlow MR; Cyrus PA; Nadel A; Lahiri DK; Brashear A; Gulanski B
Neurology; 1999 Dec; 53(9):2010-6. PubMed ID: 10599773
[TBL] [Abstract][Full Text] [Related]
56. Memantine for dementia.
Areosa SA; Sherriff F
Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
[TBL] [Abstract][Full Text] [Related]
57. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
[TBL] [Abstract][Full Text] [Related]
59. Memantine for dementia.
McShane R; Areosa Sastre A; Minakaran N
Cochrane Database Syst Rev; 2006 Apr; (2):CD003154. PubMed ID: 16625572
[TBL] [Abstract][Full Text] [Related]
60. Disease progression meta-analysis model in Alzheimer's disease.
Ito K; Ahadieh S; Corrigan B; French J; Fullerton T; Tensfeldt T;
Alzheimers Dement; 2010 Jan; 6(1):39-53. PubMed ID: 19592311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]